An investigation on behalf of investors in Omeros Corporation (NASDAQ:OMER) shares over potential wrongdoing at Omeros Corporation was announced.

San Diego, CA -- (SBWire) -- 12/14/2021 --Certain directors of Omeros Corporation are under investigation over potential breaches of fiduciary duties.

Investors who purchased shares of Omeros Corporation (NASDAQ: OMER) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Omeros Corporation directors breached their fiduciary duties and caused damage to the company and its shareholders.

Seattle, WA based Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases.

On October 1, 2021, Omeros Corporation (NASDAQ: OMER) announced that the U.S. Food and Drug Administration ("FDA") had identified deficiencies with the Company's Biologics License Application for its drug candidate narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), which "preclude discussion of labeling and post-marketing requirements/commitments at this time." Though the "FDA did not provide specific details of the deficiencies in its notification[,]" the Company stated that it "does not currently expect any resolution to occur by the October 17, 2021 target action date under the Prescription Drug User Fee Act (PDUFA)." Shares of Omeros Corporation (NASDAQ: OMER) declined from $16.30 per share on September 24, 2021, to $6.52 per share on October 8, 2021.

Those who purchased shares of Omeros Corporation (NASDAQ: OMER) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.